Receive our newsletter – data, insights and analysis delivered to you
  1. News
September 7, 2021

Southern Cross University initiates trial of CBD for sleep disturbances

The trial will have nearly 438 healthy subjects aged 18 to 65 years enrolled at four sites in Australia. 

Scientists at Southern Cross University in Australia have launched a large clinical trial assessing the potential of over-the-counter botanical cannabidiol (CBD) products to treat sleep disturbances in healthy subjects.

A compound found within the cannabis plant, CBD possesses no psychoactive properties.

Recent research has shown that CBD can help improve sleep disturbance symptoms and mood.

Funded by domestic hemp company Ecofibre, the trial will analyse the efficacy of its Ananda Hemp CBD extract versus placebo in subjects with self-reported alterations in sleep disturbances.

The randomised, placebo-controlled trial aims to enrol a total of 438 healthy subjects aged 18 to 65 years at four sites in Lismore, Brisbane, Sydney and Melbourne.

The subjects will include those with self-reported poor sleep, including people with problems related to starting and maintaining sleep or those who wake up earlier than preferred.

Content from our partners
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide
Why Asia-Pacific is the next frontier for decentralized clinical trials

In the initial stage, each subject will receive the product for two weeks to detect the accurate dosage followed by treatment for eight more weeks to assess the quality of sleep and their wellbeing.

Trial lead investigator Dr Janet Schloss said: “Approximately 33%-45% of Australians currently suffer from sleep disturbances, which can impact both our physical and mental health when left untreated.

“We are currently investigating if a low-dose botanical CBD soft gel will assist people with sleep disturbance compared to a placebo, which is an inactive substance.”

In December 2020, the Therapeutic Goods Association (TGA) down-scheduled some low-dose CBD products to a Schedule 3 (pharmacist-only medicine) from a Schedule 4 (prescription medicine).

The latest trial follows Australian legalisation announced earlier this year permitting the over-the-counter purchase of products with CBD as a pharmacist-only drug.

According to The Sleep Foundation, poor quality sleep can damage the immune response and could cause flare-ups of various chronic illnesses and diseases.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU